ImmuPharma (LSE:IMM) has reported progress in strengthening the intellectual property and scientific foundation of its P140 autoimmune technology platform. The company recently received a supportive first Combined Search and Examination Report for a UK patent application submitted in September 2025. As the next step, management plans to file under the Patent Cooperation Treaty to extend patent protection across major commercial markets, highlighting the strategic importance of P140 within its development pipeline.
Further supporting the programme, a new study designed to stress test the associated diagnostic and reinforce statistical reliability delivered positive results that strengthen the patent position. In parallel, the company is preparing a scientific manuscript explaining the mechanism of action of P140 for submission to a peer-reviewed journal. ImmuPharma also continues to engage with potential partners, including meetings at the Bio Europe Spring conference, as it works toward securing a licensing agreement for P140 in 2026. Such a deal could play a significant role in shaping the company’s future revenue prospects and strategic positioning within the sector.
From an outlook perspective, the company remains constrained by weak financial fundamentals, including minimal revenue, ongoing losses, continued cash burn and negative equity. Technical indicators present a mixed picture but show some modest support relative to the 200-day average. Valuation metrics remain challenging due to the lack of profitability and the absence of a dividend.
More about ImmuPharma PLC
ImmuPharma PLC is a UK-listed specialty biopharmaceutical company focused on the discovery and development of peptide-based therapies. Its research programmes target autoimmune conditions and anti-infective indications, positioning the company within a specialised segment of the biopharmaceutical industry focused on precision treatments for immune-related diseases.
Leave a Reply